science
Study Describes Low-Cost Blood Test for Detecting Multiple Diseases Using Cell-Free DNA Methylation
Researchers have developed a blood test that uses cell-free DNA methylation to detect multiple diseases at a low cost. The test analyzes methylation patterns in blood samples to identify conditions such as cancer and cardiovascular disease. This approach aims to enable early detection through a simple, non-invasive method.
Apr 6, 4:41 PM·1m read1 source
ER
Oleg Yunakov / Wikimedia (CC BY-SA 4.0)Audio version
Tap play to generate a narrated version.
A new blood test utilizing cell-free DNA methylation has been reported for detecting multiple diseases at a low cost. The test examines methylation patterns in circulating cell-free DNA from blood samples. According to @EricTopol, this method could identify various conditions including cancers, cardiovascular diseases, and autoimmune disorders.
The technology relies on analyzing epigenetic modifications, specifically DNA methylation, which are chemical tags on DNA that regulate gene expression. Cell-free DNA is released into the bloodstream from dying cells and carries information about the body's health status. The test processes blood samples to detect abnormal methylation signatures associated with specific diseases.
Development of this test involved training machine learning models on large datasets of methylation profiles from healthy and diseased individuals. @EricTopol reported that the approach achieves high sensitivity and specificity for multiple disease types. Costs are kept low through streamlined sequencing and analysis protocols, potentially under $100 per test.
This test could be applied in routine screening programs for early disease detection.
It affects patients at risk for chronic conditions by offering a single blood draw for multi-disease assessment. Next steps include larger clinical trials to validate performance across diverse populations. Background on cell-free DNA testing includes prior uses in prenatal screening and cancer monitoring.
Stakes involve improving access to diagnostics in resource-limited settings. Affected groups include those with limited healthcare access, where low-cost options could increase screening rates. What happens next may involve regulatory approvals from bodies like the FDA.
Integration into clinical practice would require standardization and further studies on long-term outcomes. @EricTopol noted the test's potential for broad implementation pending validation.
